Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
复制标题
作者：
Gao J;He Q;Subudhi S;Aparicio A;Zurita-Saavedra A;Lee DH;Jimenez C;Suarez-Almazor M;Sharma P
用抗CTLA-4单克隆抗体ipilimumab靶向T细胞抑制性检查点，代表了癌症治疗免疫疗法的科学突破。然而，ipilimumab治疗也与独特的副作用有关，称为免疫相关不良事件（irAE），需要识别并使用免疫抑制剂进行管理。迄今为止，我们对伊匹单抗相关副作用的了解大多基于黑色素瘤的临床研究。在此，我们对伊匹单抗诱导的irAE以及我们在M. D.安德森癌症中心的两个不同的临床试验方案。
Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here, we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at M. D. Anderson Cancer Center on two different clinical trial protocols.